Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
London close: Stocks end down as GSK tumbles on litigation woes
(Sharecast News) - London stocks reversed earlier gains to end down on Monday, with GSK weighing heavily on the top-flight index on the back of the latest US court ruling on its heartburn drug Zantac. The FTSE 100 closed 0.2% lower at 8,262.75, with all eyes on an expected rate cut by the European Central Bank this week.
Chris Beauchamp, chief market analyst at IG, said: "The morning session for Europe and US futures suggested we might see more gains, but aside from small gains for the Nasdaq 100 Wall Street has failed to make progress, while European markets have given back some of their gains.
"A contraction in US manufacturing activity and signs of strength in European gas prices have given investors reason to put their bullishness on hold."
On the UK macro front, a survey out earlier showed the manufacturing sector returned to growth in May, with output growing at the fastest pace in more than two years.
The S&P Global manufacturing purchasing managers' index rose to 51.2 from 49.1 in April, coming in above the 50.0 mark that separates contraction from expansion. This marked the highest reading since July 2022 but was just a touch lower than the flash estimate of 51.3.
The survey also showed that business optimism hit its highest level in 27 months, with 63% of companies expecting output to expand over the coming year.
Rob Dobson, director at S&P Global Market Intelligence, said: "May saw a solid revival of activity in the UK manufacturing sector, with levels of production and new business both rising at the quickest rates since early-2022. The breadth of the recovery was also a positive, with concurrent output and new order growth registered for all of the main subindustries (consumer, intermediate and investment goods) and all company size categories for the first time in over two years.
"The latest PMI survey data provided a mixed picture for price pressures at manufacturers, however. At the factory gate, output charge inflation strengthened for the fifth successive month and to its highest level in a year. That said, a solid easing in the rate of increase in input costs should help prevent price pressures from becoming embedded."
In corporate news, GSK tumbled after a US court ruled that jury trials could hear expert witnesses in cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.
A judge in the Delaware State Court ruled that scientific experts would be able to testify there is a link between the plaintiffs' illnesses and their exposure to probable human carcinogens, through the Zantac drug.
Russ Mould, investment director at AJ Bell, said: "Investors had reached a point of some comfort with GSK's Zantac issue as a series of US lawsuits linking the heartburn drug to cancer appeared to be running out of steam.
"However, a judge in Delaware has thrown a significant spanner into the works by giving the green light for 70,000 cases to go forward and by allowing expert witnesses to testify in court that the drug may cause cancer.
"GSK and the other parties involved, Pfizer and Sanofi, have made clear they disagree with the ruling and GSK has said it will mount an appeal.
"However, in the short term this just pours more uncertainty over the investment case. An uncomfortable comparison for GSK management can be drawn with AstraZeneca, which has left its counterpart for dust in recent times and is forging ahead with ambitious growth targets."
Baltic Classifieds fell after Antler, which is controlled by funds advised by Apax, sold 40m shares in a placing.
On the upside, JD Sports surged, having slumped on Friday after full-year results.
St James's Place rallied after an upgrade to 'overweight' from 'neutral' at , which cited an attractive valuation and reducing uncertainty. "Whilst we believe that negative news is largely behind us, this has not been reflected in valuation, with St James's Place trading at 7x FY25e," it said.
"We expect that sentiment will improve given the resilience in gross flows, and we see upside to consensus net flow estimates."
Quilter was also up as JPM lifted the shares to 'overweight' from 'neutral', saying it was "looking beyond the redress".
National Grid got a boost as Citi upped the shares to 'buy' from 'neutral' and lifted the price target to 985p from 920p, citing an attractive risk/reward.
Pets At Home was lifted by an upgrade to 'buy' from 'hold' at Liberum, which increased its price target to 360p from 290p.
Hipgnosis edged up after it agreed the terms of an improved cash offer from US private equity firm Blackstone, at $1.31 a share, up from $1.30.
Market Movers
FTSE 100 (UKX) 8,262.75 -0.15% FTSE 250 (MCX) 20,900.49 0.82% techMARK (TASX) 4,836.84 -0.17%
FTSE 100 - Risers
JD Sports Fashion (JD.) 133.95p 5.06% St James's Place (STJ) 523.00p 4.68% Entain (ENT) 705.40p 4.47% easyJet (EZJ) 475.40p 3.35% Land Securities Group (LAND) 670.00p 2.68% Ocado Group (OCDO) 382.70p 2.44% International Consolidated Airlines Group SA (CDI) (IAG) 175.40p 2.33% 3i Group (III) 2,926.00p 2.20% Rightmove (RMV) 544.60p 2.14% Airtel Africa (AAF) 124.50p 2.13%
FTSE 100 - Fallers
GSK (GSK) 1,598.00p -9.54% Ashtead Group (AHT) 5,516.00p -3.02% Pearson (PSON) 932.80p -1.60% BP (BP.) 481.20p -1.42% Severn Trent (SVT) 2,357.00p -1.22% Compass Group (CPG) 2,168.00p -1.09% Intermediate Capital Group (ICG) 2,286.00p -1.04% Shell (SHEL) 2,782.50p -1.03% United Utilities Group (UU.) 1,006.00p -0.98% Beazley (BEZ) 683.50p -0.94%
FTSE 250 - Risers
Tritax Eurobox (GBP) (EBOX) 59.90p 11.34% Ferrexpo (FXPO) 45.95p 10.59% Pets at Home Group (PETS) 322.60p 8.91% TUI AG Reg Shs (DI) (TUI) 575.50p 6.97% Wizz Air Holdings (WIZZ) 2,414.00p 5.32% Auction Technology Group (ATG) 549.00p 5.17% Quilter (QLT) 123.40p 4.75% Elementis (ELM) 156.40p 4.13% Essentra (ESNT) 171.20p 3.76% Helios Towers (HTWS) 129.40p 3.69%
FTSE 250 - Fallers
Baltic Classifieds Group (BCG) 242.50p -5.46% Harbour Energy (HBR) 322.30p -2.33% Oxford Instruments (OXIG) 2,450.00p -2.00% HarbourVest Global Private Equity Limited A Shs (HVPE) 2,345.00p -1.88% Energean (ENOG) 1,171.00p -1.84% Pennon Group (PNN) 611.00p -1.77% Barr (A.G.) (BAG) 613.00p -1.61% Me Group International (MEGP) 180.00p -1.53% CMC Markets (CMCX) 277.50p -1.42% Keller Group (KLR) 1,272.00p -1.40%
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.